In conclusion, ROR1 protein expression data from these investigated haematological indications has a heterogeneous prevalence, suggesting that ROR1 as a tumour target for novel therapies should be considered with different biomarker strategies for patient selection pending on levels of tumoral ROR1 positivity. Here, ROR1 is linked to neoplasm.